Citigroup
ATOS icon

Citigroup’s Atossa Therapeutics ATOS Stock Holding History

Citigroup’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,872
Closed -$59.3K – 5646
2025
Q1 		$59.3K Sell
5,872
-796
-12% -$9.66K ﹤0.01% 4833
2024
Q4 		$94.4K Buy
6,668
+536
+9% +$10.5K ﹤0.01% 4869
2024
Q3 		$140K Buy
6,132
+2,588
+73% +$52.2K ﹤0.01% 4596
2024
Q2 		$63.3K Sell
3,544
-8,647
-71% -$191K ﹤0.01% 4457
2024
Q1 		$329K Buy
+12,191
New +$196K ﹤0.01% 3789
2023
Q3 		– Sell
-11
Closed -$214 – 5667
2023
Q2 		$214 Buy
+11
New +$133 ﹤0.01% 5426
2022
Q3 		– Sell
-81
Closed -$1K – 5818
2022
Q2 		$1K Sell
81
-319
-80% -$5.03K ﹤0.01% 5979
2022
Q1 		$8K Sell
400
-1,586
-80% -$32.2K ﹤0.01% 5626
2021
Q4 		$48K Buy
1,986
+739
+59% +$27K ﹤0.01% 5079
2021
Q3 		$61K Buy
1,247
+209
+20% +$12.2K ﹤0.01% 4635
2021
Q2 		$98K Buy
1,038
+371
+56% +$19.6K ﹤0.01% 4520
2021
Q1 		$21K Buy
+667
New +$24.4K ﹤0.01% 5206
2020
Q4 		– Sell
-93
Closed -$3K – 7356
2020
Q3 		$3K Buy
+93
New +$4.47K ﹤0.01% 7191
2016
Q1 		– Hold
0
– – – 7447
2015
Q4 		– Hold
0
– – – 7537
2015
Q3 		– Sell
-1
Closed -$4K – 7364
2015
Q2 		$4K Buy
+1
New +$3.99K ﹤0.01% 6839
2015
Q1 		– Sell
-1
Closed -$3K – 7191
2014
Q4 		$3K Hold
1
– – ﹤0.01% 6781
2014
Q3 		$4K Hold
1
– – ﹤0.01% 6626
2014
Q2 		$6K Hold
1
– – ﹤0.01% 6362
2014
Q1 		$6K Buy
+1
New +$5.92K ﹤0.01% 6529
2013
Q4 		– Hold
0
– – – 6769
2013
Q3 		– Hold
0
– -$1K – 6791
2013
Q2 		– Hold
0
– – – 6603

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's ATOS Position: Q2 2025 in Review

Citigroup sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 5,872 shares — an estimated $59.3K sold.

Citigroup first reported a position in ATOS in Q1 2014 and held it in 18 quarters. The position peaked at $329K in Q1 2024. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • Citigroup reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Citigroup sold 5,872 Atossa Therapeutics shares in Q2 2025, an estimated $59.3K.
  • Citigroup first reported a position in Atossa Therapeutics in Q1 2014 and held it in 18 quarters.
  • Citigroup's Atossa Therapeutics position peaked at $329K in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.